{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:28:35Z","timestamp":1777285715153,"version":"3.51.4"},"reference-count":91,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004385","name":"UGent BOF starting","doi-asserted-by":"publisher","award":["202409\/004"],"award-info":[{"award-number":["202409\/004"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Background: Human herpesviruses are double-stranded DNA viruses of which eight types have been identified at present. Herpesvirus infection comprises an active lytic phase and a lifelong latency phase with the possibility of reactivation. These infections are highly prevalent worldwide and can lead to a broad spectrum of clinical manifestations, ranging from mild symptoms to severe disease, particularly in immunocompromised individuals. Clustered regularly interspaced palindromic repeats (CRISPR)-based therapy is an interesting alternative to current antiviral drugs, which fail to cure latent infections and are increasingly challenged by viral resistance. Objective: This scoping review aimed to summarize the current state of CRISPR-based antiviral strategies against herpesvirus infections, highlighting the underlying mechanisms, study design and outcomes, and challenges for clinical implementation. Design: A literature search was conducted in the databases PubMed and Web of Science, using both a general and an individual approach for each herpesvirus. Results: This scoping review identified five main mechanisms of CRISPR-based antiviral therapy against herpesvirus infections in vitro and\/or in vivo. First, CRISPR systems can inhibit the active lytic replication cycle upon targeting viral lytic genes or host genes. Second, CRISPR technologies can remove latent viral genomes from infected cells by targeting viral genes essential for latency maintenance or destabilizing the viral genome. Third, reactivation of multiple latent herpesvirus infections can be inhibited by CRISPR-Cas-mediated editing of lytic viral genes, preventing a flare-up of clinical symptoms and reducing the risk of viral transmission. Fourth, CRISPR systems can purposefully induce viral reactivation to enhance recognition by the host immune system or improve the efficacy of existing antiviral therapies. Fifth, CRISPR technology can be applied to develop or enhance the efficiency of cellular immunotherapy. Conclusions: Multiple studies demonstrate the potential of CRISPR-based antiviral strategies to target herpesvirus infections through various mechanisms in vitro and in vivo. However, aspects regarding the delivery and biosafety of CRISPR systems, along with the time window for treatment, require further investigation before broad clinical implementation can be realized.<\/jats:p>","DOI":"10.3390\/pathogens14070654","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:42:06Z","timestamp":1751355726000},"page":"654","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Applying CRISPR Technologies for the Treatment of Human Herpesvirus Infections: A Scoping Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2820-2136","authenticated-orcid":false,"given":"Chlo\u00eb","family":"Hanssens","sequence":"first","affiliation":[{"name":"Laboratory of Virology, Department of Translational Physiology, Infectiology and Public Health, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1598-3057","authenticated-orcid":false,"given":"Jolien","family":"Van Cleemput","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Department of Translational Physiology, Infectiology and Public Health, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijantimicag.2013.04.023","article-title":"Management of herpesvirus infections","volume":"42","author":"Evans","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Agut, H., Bonnafous, P., and Gautheret-Dejean, A. (2016). Human Herpesviruses 6A, 6B, and 7. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.DMIH2-0007-2015"},{"key":"ref_3","first-page":"95","article-title":"Varicella-zoster virus infection: Natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"New Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: Global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.1998.7530193.x","article-title":"Comparison of seroprevalences of human herpesvirus-6 and-7 in healthy blood donors from nine countries","volume":"75","author":"Krueger","year":"1998","journal-title":"Vox Sang."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3390\/v6114178","article-title":"Epidemiology and transmission of Kaposi\u2019s sarcoma-associated herpesvirus","volume":"6","author":"Minhas","year":"2014","journal-title":"Viruses"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Smatti, M.K., Al-Sadeq, D.W., Ali, N.H., Pintus, G., Abou-Saleh, H., and Nasrallah, G.K. (2018). Epstein\u2013Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: An update. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00211"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/21505594.2021.1982373","article-title":"Pathogenesis and virulence of herpes simplex virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Virulence"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pantry, S.N., and Medveczky, P.G. (2017). Latency, Integration, and Reactivation of Human Herpesvirus-6. Viruses, 9.","DOI":"10.3390\/v9070194"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Stoeger, T., and Adler, H. (2018). \u201cNovel\u201d Triggers of Herpesvirus Reactivation and Their Potential Health Relevance. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.03207"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.medmal.2016.09.004","article-title":"Update on infections with human herpesviruses 6A, 6B, and 7","volume":"47","author":"Agut","year":"2017","journal-title":"Med. Mal. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000018381","article-title":"Cytomegalovirus infection in normal and immunocompromised humans. A review","volume":"200","author":"Drago","year":"2000","journal-title":"Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","article-title":"Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_16","first-page":"199","article-title":"Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV8)-review","volume":"58","author":"Iftode","year":"2020","journal-title":"Rom. J. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kennedy, P.G.E., and Gershon, A.A. (2018). Clinical Features of Varicella-Zoster Virus Infection. Viruses, 10.","DOI":"10.3390\/v10110609"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/09674845.2021.1903683","article-title":"Infectious Mononucleosis: Diagnosis and clinical interpretation","volume":"78","author":"Naughton","year":"2021","journal-title":"Br. J. Biomed. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcv.2004.11.008","article-title":"The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent","volume":"32","author":"Ward","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cnur.2020.05.004","article-title":"Herpes Simplex Virus: Epidemiology, Diagnosis, and Treatment","volume":"55","author":"Cole","year":"2020","journal-title":"Nurs. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.idc.2009.10.008","article-title":"Cytomegalovirus pneumonia: Community-acquired pneumonia in immunocompetent hosts","volume":"24","author":"Cunha","year":"2010","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40475-022-00255-8","article-title":"Herpesvirus-Associated Encephalitis: An Update","volume":"9","author":"Matthews","year":"2022","journal-title":"Curr. Trop. Med. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000443198","article-title":"Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences","volume":"1","author":"Nakase","year":"2016","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-981-10-7230-7_16","article-title":"Pathological Features of Kaposi\u2019s Sarcoma-Associated Herpesvirus Infection","volume":"1045","author":"Katano","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yu, H., and Robertson, E.S. (2023). Epstein\u2013Barr Virus History and Pathogenesis. Viruses, 15.","DOI":"10.3390\/v15030714"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sadowski, L.A., Upadhyay, R., Greeley, Z.W., and Margulies, B.J. (2021). Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and-2. Viruses, 13.","DOI":"10.3390\/v13071228"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109577","DOI":"10.1016\/j.cellsig.2020.109577","article-title":"CRISPR system: Discovery, development and off-target detection","volume":"70","author":"Chen","year":"2020","journal-title":"Cell Signal"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Horodecka, K., and D\u00fcchler, M. (2021). CRISPR\/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116072"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lee, C. (2019). CRISPR\/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules, 24.","DOI":"10.3390\/molecules24071349"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41586-019-0908-x","article-title":"CasX enzymes comprise a distinct family of RNA-guided genome editors","volume":"566","author":"Liu","year":"2019","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Aimola, G., Wight, D.J., Flamand, L., and Kaufer, B.B. (2023). Excision of Integrated Human Herpesvirus 6A Genomes Using CRISPR\/Cas9 Technology. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.00764-23"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Brackett, K., Mungale, A., Lopez-Isidro, M., Proctor, D.A., Najarro, G., and Arias, C. (2021). CRISPR Interference Efficiently Silences Latent and Lytic Viral Genes in Kaposi\u2019s Sarcoma-Associated Herpesvirus-Infected Cells. Viruses, 13.","DOI":"10.3390\/v13050783"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ding, J., Zhang, H., Dai, T., Gao, X., Yin, Z., Wang, Q., Long, M., and Tan, S. (2024). TPGS-b-PBAE Copolymer-Based Polyplex Nanoparticles for Gene Delivery and Transfection In Vivo and In Vitro. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020213"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Elbasani, E., Falasco, F., Gramolelli, S., Nurminen, V., G\u00fcnther, T., Weltner, J., Balboa, D., Grundhoff, A., Otonkoski, T., and Ojala, P.M. (2020). Kaposi\u2019s Sarcoma-Associated Herpesvirus Reactivation by Targeting of a dCas9-Based Transcription Activator to the ORF50 Promoter. Viruses, 12.","DOI":"10.3390\/v12090952"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Karpov, D.S., Demidova, N.A., Kulagin, K.A., Shuvalova, A.I., Kovalev, M.A., Simonov, R.A., Karpov, V.L., Snezhkina, A.V., Kudryavtseva, A.V., and Klimova, R.R. (2022). Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR\/Cas9 and CRISPR\/CasX Systems. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314847"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Roehm, P.C., Shekarabi, M., Wollebo, H.S., Bellizzi, A., He, L.F., Salkind, J., and Khalili, K. (2016). Inhibition of HSV-1 Replication by Gene Editing Strategy. Sci. Rep., 6.","DOI":"10.1038\/srep23146"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1249558","DOI":"10.1080\/2162402X.2016.1249558","article-title":"CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer","volume":"6","author":"Su","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/JVI.02183-18","article-title":"Reduction of Kaposi\u2019s Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene","volume":"93","author":"Tso","year":"2019","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"van Diemen, F.R., Kruse, E.M., Hooykaas, M.J., Bruggeling, C.E., Sch\u00fcrch, A.C., van Ham, P.M., Imhof, S.M., Nijhuis, M., Wiertz, E.J., and Lebbink, R.J. (2016). CRISPR\/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005701"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13157","DOI":"10.1073\/pnas.1410785111","article-title":"RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2023.08.021","article-title":"In vivo CRISPR gene editing in patients with herpetic stromal keratitis","volume":"31","author":"Wei","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wu, B., Yee, M.B., Goldstein, R.S., and Kinchington, P.R. (2022). Antiviral Targeting of Varicella Zoster Virus Replication and Neuronal Reactivation Using CRISPR\/Cas9 Cleavage of the Duplicated Open Reading Frames 62\/71. Virusesl, 14.","DOI":"10.3390\/v14020378"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","article-title":"Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice","volume":"39","author":"Yin","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101303","DOI":"10.1016\/j.omtm.2024.101303","article-title":"CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model","volume":"32","author":"Amrani","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.omtn.2024.102282","article-title":"Suppression of HSV-1 infection and viral reactivation by CRISPR-Cas9 gene editing in 2D and 3D culture models","volume":"35","author":"Bellizzi","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.omtm.2020.05.011","article-title":"Single AAV-Mediated CRISPR-SaCas9 Inhibits HSV-1 Replication by Editing ICP4 in Trigeminal Ganglion Neurons","volume":"18","author":"Chen","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"de Sousa, R.M.P., Garcia, L.S., Lemos, F.S., de Campos, V.S., Machado Ferreira, E., de Almeida, N.A.A., Maron-Gutierrez, T., de Souza, E.M., and de Paula, V.S. (2024). CRISPR\/Cas9 Eye Drop HSV-1 Treatment Reduces Brain Viral Load: A Novel Application to Prevent Neuronal Damage. Pathogens, 13.","DOI":"10.3390\/pathogens13121087"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1134\/S0026893319010059","article-title":"[A Plasmid-Expressed CRISPR\/Cas9 System Suppresses Replication of HSV Type I in a Vero Cell Culture]","volume":"53","author":"Karpov","year":"2019","journal-title":"Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5603\/FHC.a2020.0020","article-title":"A knockdown of the herpes simplex virus type-1 gene in all-in-one CRISPR vectors","volume":"58","author":"Khodadad","year":"2020","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e51662","DOI":"10.7554\/eLife.51662","article-title":"Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR\/Cas9","volume":"8","author":"Oh","year":"2019","journal-title":"Elife"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14715\/cmb\/2023.69.7.3","article-title":"CRISPR\/Cas-9 vector system: Targets UL-39 and inhibits Simplexvirus humanalpha1 (HSV-1) replication in vitro","volume":"69","author":"Raposo","year":"2023","journal-title":"Cell Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.apsb.2023.10.004","article-title":"Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo","volume":"14","author":"Wan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1038\/s41467-022-35425-9","article-title":"Engineering antiviral immune-like systems for autonomous virus detection and inhibition in mice","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ying, M., Wang, H., Liu, T., Han, Z., Lin, K., Shi, Q., Zheng, N., Ye, T., Gong, H., and Xu, F. (2023). CLEAR Strategy Inhibited HSV Proliferation Using Viral Vectors Delivered CRISPR-Cas9. Pathogens, 12.","DOI":"10.3390\/pathogens12060814"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41467-025-55928-5","article-title":"Herpesviruses mimic zygotic genome activation to promote viral replication","volume":"16","author":"Neugebauer","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.11.2.8","article-title":"Targeting NECTIN-1 Based on CRISPR\/Cas9 System Attenuated the Herpes Simplex Virus Infection in Human Corneal Epithelial Cells In Vitro","volume":"11","author":"Li","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virusres.2017.04.019","article-title":"Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR\/Cas9","volume":"244","author":"Yuen","year":"2018","journal-title":"Virus Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13027-019-0246-5","article-title":"CRISPR\/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth","volume":"14","author":"Huo","year":"2019","journal-title":"Infect. Agents Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1039\/D3TB02926C","article-title":"Post cross-linked ROS-responsive poly(\u03b2-amino ester)-plasmid polyplex NPs for gene therapy of EBV-associated nasopharyngeal carcinoma","volume":"12","author":"Yuan","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sugiokto, F.G., and Li, R. (2024). Targeted eradication of EBV-positive cancer cells by CRISPR\/dCas9-mediated EBV reactivation in combination with ganciclovir. mBio, 15.","DOI":"10.1128\/mbio.00795-24"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Gergen, J., Coulon, F., Creneguy, A., Elain-Duret, N., Gutierrez, A., Pinkenburg, O., Verhoeyen, E., Anegon, I., Nguyen, T.H., and Halary, F.A. (2018). Multiplex CRISPR\/Cas9 system impairs HCMV replication by excising an essential viral gene. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192602"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00705-020-04687-3","article-title":"Targeting human cytomegalovirus IE genes by CRISPR\/Cas9 nuclease effectively inhibits viral replication and reactivation","volume":"165","author":"Xiao","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e0080221","DOI":"10.1128\/JVI.00802-21","article-title":"Targeting Conserved Sequences Circumvents the Evolution of Resistance in a Viral Gene Drive against Human Cytomegalovirus","volume":"95","author":"Walter","year":"2021","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1038\/s41467-020-18678-0","article-title":"Viral gene drive in herpesviruses","volume":"11","author":"Walter","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JVI.00628-19","article-title":"CRISPR\/Cas9-Mediated Knockout and In Situ Inversion of the ORF57 Gene from All Copies of the Kaposi\u2019s Sarcoma-Associated Herpesvirus Genome in BCBL-1 Cells","volume":"93","author":"BeltCappellino","year":"2019","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12985-021-01527-x","article-title":"Targeting the Kaposi\u2019s sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells","volume":"18","author":"Haddad","year":"2021","journal-title":"Virol. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1002\/jmv.27046","article-title":"Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR\/Cas9-mediated targeting of a major viral latent protein","volume":"93","author":"Ju","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bbrc.2020.10.030","article-title":"CRISPR\/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi\u2019s sarcoma-associated herpesvirus","volume":"533","author":"Liang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/bloodadvances.2020001977","article-title":"Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ymthe.2020.06.002","article-title":"CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation","volume":"28","author":"Kaeuferle","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Koukoulias, K., Papayanni, P.G., Georgakopoulou, A., Alvanou, M., Laidou, S., Kouimtzidis, A., Pantazi, C., Gkoliou, G., Vyzantiadis, T.A., and Spyridonidis, A. (2021). \u201cCerberus\u201d T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.608701"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.omtm.2023.06.007","article-title":"A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell transfer applications","volume":"30","author":"Palianina","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Braun, T., Pruene, A., Darguzyte, M., Stein, A.F.V., Nguyen, P.-H., Wagner, D.L., Kath, J., Roig-Merino, A., Heuser, M., and Riehm, L.L. (2023). Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1086433"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Baddeley, H.J.E., and Isalan, M. (2021). The Application of CRISPR\/Cas Systems for Antiviral Therapy. Front. Genome Ed., 3.","DOI":"10.3389\/fgeed.2021.745559"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Qiu, S., Zhang, X., and Chen, W. (2018). Optimized DNA electroporation for primary human T cell engineering. BMC Biotechnol., 18.","DOI":"10.1186\/s12896-018-0419-0"},{"key":"ref_83","first-page":"192","article-title":"In Vivo Gene Delivery into Mouse Mammary Epithelial Cells Through Mammary Intraductal Injection","volume":"10","author":"Bu","year":"2023","journal-title":"J. Vis. Exp. JoVE"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Alexander, E., and Leong, K.W. (2024). Discovery of nanobodies: A comprehensive review of their applications and potential over the past five years. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02900-y"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s44222-025-00277-7","article-title":"Extracellular vesicles for the delivery of gene therapy","volume":"3","author":"Obuchi","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.omtm.2019.09.003","article-title":"Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors","volume":"15","author":"Eichhoff","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.omtm.2018.10.006","article-title":"Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes","volume":"12","author":"Frank","year":"2019","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.cgt.7700337","article-title":"Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells","volume":"8","author":"Li","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI136225","article-title":"Herpesvirus latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J. Clin. Investig."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/7\/654\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:25Z","timestamp":1760032945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/7\/654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":91,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["pathogens14070654"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14070654","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}